share_log

EF Hutton Initiates Coverage On Lantern Pharma With Buy Rating, Announces Price Target of $11

Benzinga Real-time News ·  Nov 1, 2022 16:56

EF Hutton analyst Michael King initiates coverage on Lantern Pharma (NASDAQ:LTRN) with a Buy rating and announces Price Target of $11.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment